Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
Effective therapeutic options are needed for community-onset urinary tract infections due to Escherichia coli strains that produce CTX-M extended-spectrum beta-lactamases. We examined 46 urinary isolates producing CTX-M against several oral or long-acting parenteral antimicrobial agents. Approximately 90% were susceptible to fosfomycin and to a combination of cefdinir plus amoxicillin-clavulanate. All were susceptible to ertapenem.
Prakash
Vidhya
V
San Antonio Military Medical Center, Infectious Disease Service, San Antonio, Texas 78234, USA.
Lewis
James S
JS
Herrera
Monica L
ML
Wickes
Brian L
BL
Jorgensen
James H
JH
D000284:Administration, Oral; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000077525:Cefdinir; D002511:Cephalosporins / Q000494:pharmacology; D003428:Cross Infection / Q000382:microbiology; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000235:genetics; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D005578:Fosfomycin / Q000494:pharmacology; D006801:Humans; D007263:Infusions, Parenteral; D008826:Microbial Sensitivity Tests; D010045:Outpatients; D014552:Urinary Tract Infections / Q000382:microbiology*; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D047090:beta-Lactams; D005578:Fosfomycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000077525:Cefdinir; D001618:beta-Lactamases; D000077727:Ertapenem